RiAtlas
RiAtlas is an Italian digital health company and University of Salerno spin-off that builds EU MDR-certified AI and IoT Software Medical Devices for remote patient monitoring, oncology, neurological telemonitoring, and clinical trials, sold primarily to Italian hospitals and pharmaceutical companies.
- Company typePrivate
- Founded2017
- HeadquartersFisciano, Italy
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What RiAtlas does
RiAtlas S.r.l. is an Italian digital health company founded in September 2017 as an authorized spin-off of the University of Salerno. Operating from offices in Novi Velia, Fisciano, Penta, and Torre Annunziata, the company builds AI- and IoT-enabled Software Medical Devices for remote patient monitoring, clinical decision support, and continuity of care. Its core product, RiAtlas Healthcare, was upgraded to EU MDR Class IIa certification in late 2024, and is accompanied by RiAtlas Oncology (CE Class I, for cancer care pathways), NIA (a Class I telemonitoring solution for neurological diseases developed with NeMO Lab), and RiAtlas Clinical Trial (an add-on module for pharmaceutical companies). The underlying AI engine includes an Intelligent Classifier that maps patient state to the WHO ICF taxonomy, an incremental learning-based alerting system for early clinical risk detection, and context data visualization correlated over time, with two granted Italian patents protecting the core methods and HL7-FHIR interoperability underpinning the platform.
The company generates revenue through four streams: SaaS subscriptions for healthcare facilities, sale and licensing of certified medical device software (CE Class I and Class IIa), innovation and technology transfer consultancy services, and clinical trial management solutions for pharmaceutical companies. GTM is primarily direct enterprise sales to Italian public and private hospitals, pharmaceutical companies, and the national health system (SSN), supplemented by qualified SaaS provider status on the AgID Cloud Marketplace for public-sector procurement and event-driven demand generation through webinars and industry conferences. Named customers and validation partners include IRCCS Fondazione Pascale, Università della Campania Luigi Vanvitelli, NeMO Lab, and unnamed pharmaceutical companies. The company is structured as an Italian innovative startup (start-up innovativa) and PMI innovativa, has not disclosed any traditional venture capital or private equity funding, and has operated primarily on grant-based non-dilutive capital from EIT Health, Facebook AI Open Loop, Regione Campania, and LVenture Group.
RiAtlas firmographics
Firmographics- Name
- RiAtlas
- Legal name
- RiAtlas S.r.l.
- Website
- https://riatlas.it
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RiAtlas is an Italian digital health company and University of Salerno spin-off that builds EU MDR-certified AI and IoT Software Medical Devices for remote patient monitoring, oncology, neurological telemonitoring, and clinical trials, sold primarily to Italian hospitals and pharmaceutical companies.
- Ownership category
- akta.pro rank
RiAtlas industry classification
Industry- Product category
- Digital Health Software (Remote Patient Monitoring & Clinical Decision Support)
- NAICS
- Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)
Keywords
Where RiAtlas is headquartered
LocationHeadquarters
- HQ city
- Fisciano
- HQ country
- Italy
- HQ region
- Europe
Offices4 records
Markets served
RiAtlas business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- SaaS Software as a Service: Subscription-based SaaS model for healthcare facilities accessing RiAtlas Healthcare and other digital health solutions through cloud-based deployment.
- Medical Device Software Sales: Sale/licensing of certified medical device software products (CE Class I and Class IIa) to healthcare providers and pharmaceutical companies.
- Innovation and Technology Transfer Services: Consultancy and services for design and development of digital health applications, implementation of medical software, and advanced tools for (big) health data analysis.
- Clinical Trial Management Solutions: Advanced clinical trial management solutions for pharmaceutical companies including Patient Reported Outcome tools and data analysis based on AI and IoT.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
RiAtlas product offering
Product offeringCore offering
RiAtlas develops and sells certified Software Medical Devices for remote patient monitoring and clinical decision support. Its flagship product, RiAtlas Healthcare, is an EU MDR Class IIa certified platform that enables management, active monitoring and remote assistance of patients transitioning from acute hospital care to therapeutic care pathways with frequent hospital readmissions. The platform combines a Patient Mobile App and Clinical Web App with an AI-based Intelligent Classifier that automatically classifies patient health status using the WHO ICF taxonomy and an Incremental Learning Alerting System for early clinical risk detection. RiAtlas also offers specialized variants (RiAtlas Oncology, NIA) and a clinical trial management module for pharmaceutical companies.
Product overview
RiAtlas offers a portfolio of digital health solutions centered on AI-powered remote patient monitoring and clinical decision support. The core offering is RiAtlas Healthcare, a Class IIa certified Software Medical Device that provides remote patient monitoring through a Patient Mobile App and Clinical Web App, enhanced by an AI-based Intelligent Classifier for ICF health status classification and early clinical risk alerting. RiAtlas Oncology is a specialized oncology-focused variant of the platform for cancer patient care pathways. NIA is a modular neurological telemonitoring solution developed with NeMO Lab, covering patients with neuromuscular diseases. RiAtlas Clinical Trial is an add-on module for pharmaceutical companies to manage clinical studies with AI and IoT tools. Innovation and Technology Transfer Services and Business Intelligence represent additional professional service offerings. All solutions are built on a common AI engine using Incremental Learning, comply with HL7-FHIR interoperability standards, GDPR, OWASP, and are delivered via SaaS on the AgID Cloud Marketplace.
Differentiator
Problem solved
Functional benefit
Brands
- RiAtlas Healthcare: Digital health solution certified as Class IIa Medical Device Software for patient management, active monitoring and remote assistance for patients starting therapeutic care pathways with frequent hospital returns in continuity of care perspective.
- RiAtlas Oncology
- RiAtlas Clinical Trial
- NIA
Products and services
- RiAtlas Healthcare RiAtlas Healthcare is an EU MDR Class IIa certified Software Medical Device for digital health, designed for the management, active monitoring and remote assistance of patients who, after an acute phase, begin a therapeutic care pathway with frequent hospital readmissions. The solution supports continuity of care and de-hospitalization through a Patient Mobile App and Clinical Web App, AI-based health status classification (WHO ICF), and an incremental learning alerting system for early clinical risk detection. It is intended for healthcare providers including public hospitals, oncology departments, and specialized clinics.
- RiAtlas Oncology RiAtlas Oncology is a specialized digital health solution developed as a Software Medical Device for the integrated management of oncological patients' therapeutic pathways. It supports active monitoring, remote assistance, and AI-powered clinical decision-making for cancer care, including remote monitoring of COVID-19 patients in home isolation. The solution was clinically validated in collaboration with IRCCS Fondazione Pascale and Università degli Studi della Campania Luigi Vanvitelli, achieving over 90% clinical concordance with physician decisions.
- NIA NIA is a modular Class I medical software device for the telemonitoring of patients with neurological diseases, developed in collaboration with NeMO Lab (NeMO Clinical Centre). It comprises a wearable device for vital parameters, a patient mobile app with neurological tests, a clinical web app, and an AI-based alert system. The solution targets patients with Parkinson's disease, stroke, neuromuscular diseases, and similar conditions requiring ongoing monitoring and care pathway management.
- RiAtlas Clinical Trial RiAtlas Clinical Trial is an advanced clinical trial management solution for pharmaceutical companies. It leverages Patient Reported Outcome tools and AI/IoT-based data analysis to monitor therapy adherence and encourage active patient participation in their own treatment pathway, helping sponsors generate clinical evidence and improve trial efficiency.
- Innovation and Technology Transfer Services Consultancy and services for the design and development of digital health applications, medical software implementation, and advanced tools for the analysis of (big) health data. The offering leverages RiAtlas's experience in healthcare innovation and digital transformation for clients including hospitals, healthcare facilities, and pharmaceutical companies.
- Business Intelligence Design and development of Business Intelligence tools for advanced analysis of healthcare data and flows, including health status classification, clinical risk detection, and population stratification, supporting administrative and managerial decision-making in healthcare organizations.
Quantifiable outcome
- Over 90% clinical concordance with physician decisions in oncology applications
- +3 more outcomes
Companies that use RiAtlas
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles3 records
RiAtlas technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
RiAtlas partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Facebook AI / Open LoopcoreRiAtlas was one of ten European companies chosen by Facebook AI to participate in the Open Loop global experimental governance program. The company contributed to creating evidence-based policy decisions for the European Commission on AI risk management, focusing on automated decision impact assessment tools for digital health.
- EricssonminorRiAtlas participated in Ericsson's innovation garages to stimulate cross-fertilization and experimentation in healthcare cybersecurity. The collaboration focused on developing GDPR-compliant blockchain technology for protecting sensitive healthcare data.
- NovartisminorRiAtlas maintains a point of contact at the Novartis Campus per l'Innovazione in Torre Annunziata, suggesting collaboration or presence within Novartis innovation ecosystem.
- AgID (Agenzia per l'Italia Digitale)coreQualified SaaS provider on the Italian government's AgID Cloud Marketplace, enabling RiAtlas Healthcare to be procured by Italian public administration healthcare facilities. The qualification certifies compliance with security, reliability, and interoperability criteria.
- NeMO Lab (Centro Clinico Nemo)coreJoint development of NIA, a telemonitoring solution for patients with neurological diseases. NeMO Lab is Italy's first technology hub for neuromuscular disease innovation, combining clinical center expertise with technology research groups and pharmaceutical industry partners.
- Istituto Nazionale Tumori – IRCCS Fondazione PascalecoreClinical validation partner for RiAtlas Oncology solution in colorectal cancer patients. During COVID-19, the institute also used RiAtlas Oncology to create a remote monitoring system for coronavirus patients in home isolation.
- Università degli Studi della Campania Luigi VanvitellicoreAcademic research partner in clinical validation of RiAtlas Oncology solution for oncology digital therapeutics and care pathway management.
- AQUA BIOTECHminorRiAtlas is a partner in the VENTIX project, co-funded under POR CAMPANIA FESR 2014/2020. The project aims to create an integrated system for home pulmonary ventilation treatment and remote monitoring of complex COPD patients.
- CariploFactoryminorRiAtlas was selected among innovative Italian SMEs for the 'Reach The Goals' report dedicated to companies operating in UN Sustainable Development Goals areas, helping increase visibility among impact investors and partners.
Scale indicators3 records
Recent moves7 records
Expansion highlights2 records
RiAtlas competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
RiAtlas social profiles
Digital presenceRiAtlas compliance and trust
Trust signalCompliance7 records
RiAtlas financial estimates
Financial estimateRevenue estimate
Valuation estimate
RiAtlas leadership team
Management profileNumber of profiles
Profiles3 records
RiAtlas funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RiAtlas M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RiAtlas
What does RiAtlas do?
RiAtlas develops and sells certified Software Medical Devices for remote patient monitoring and clinical decision support. Its flagship product, RiAtlas Healthcare, is an EU MDR Class IIa certified platform that enables management, active monitoring and remote assistance of patients transitioning from acute hospital care to therapeutic care pathways with frequent hospital readmissions. The platform combines a Patient Mobile App and Clinical Web App with an AI-based Intelligent Classifier that automatically classifies patient health status using the WHO ICF taxonomy and an Incremental Learning Alerting System for early clinical risk detection. RiAtlas also offers specialized variants (RiAtlas Oncology, NIA) and a clinical trial management module for pharmaceutical companies.
Is RiAtlas a public or private company?
RiAtlas is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was RiAtlas founded?
RiAtlas was founded in 2017. It employs 1 to 10 people.
Where is RiAtlas based?
RiAtlas is headquartered in Fisciano, Italy, in the Europe region.
How does RiAtlas make money?
Four revenue lines are on record. SaaS Software as a Service is the primary driver. The others are medical Device Software Sales, innovation and Technology Transfer Services and clinical Trial Management Solutions.
Does RiAtlas have an API?
No public API is recorded for RiAtlas.
What industry is RiAtlas in?
RiAtlas's product category is Digital Health Software (Remote Patient Monitoring & Clinical Decision Support). Its primary akta.pro industry code is HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 541511 and its SIC code is 8000.